TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31628475
Drug: Normal Nicotine
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Normal Nicotine Content (NNC) cigarettes (15.8 mg nicotine per g tobacco)
Study: 20626209
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mycophenolate mofetil (1 g twice daily)
Study: 7670428
Drug: Cognitive-behavioral treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral treatment (5-week duration including relaxation training, self-monitoring of stressors, and cognitive coping strategies)
Study: 1847127
Drug: Induction regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction regimen of external beam radiotherapy to the liver (21.0 Gy, 3.0 Gy/Fx, 10 MV photons, 4 days per week) with low-dose chemotherapy (5-Fluorouracil (FU), 500 mg, i.v.; Doxorubicin, 15 mg, i.v.) on treatment Days 1, 3, 5 and 7.
Study: 2894883
Drug: Fixed combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed combination of atenolol 50 mg and nifedipine 20 mg once daily for eight weeks
Study: 17371886
Drug: Alendronate, 70
Normalized name: Alendronate, 70 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate, 70 mg once weekly
Study: 8217176
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg of ondansetron
Study: 28215835
Drug: Early endoscopic
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early endoscopic treatment (ET) with prophylaxis until resolution
Study: 7670399
Drug: Detection of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Detection of malignant B cells in PBSC samples after chemotherapy
Study: 27175292
Drug: Methotrexate (MTX)
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate (MTX) monotherapy
Study: 25375075
Drug: Coenzyme Q10
Normalized name: Coenzyme Q10
DrugBank: Ubidecarenone (DB09270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Coenzyme Q10 supplementation (50 mg twice daily)
Study: 7674143
Drug: Higher doses
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher doses and concentrations of SH/TA-508
Study: 21707327
Drug: Testosterone gel
Normalized name: Androgel 1.62% Metered Dose Pump Testosterone Gel
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone gel
Study: 29505863
Drug: Vehicle control
Normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle control cream
Study: 28609362
Drug: Everolimus with
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Everolimus with concomitant octreotide treatment
Study: 20677963
Drug: Orthodontic oral
Normalized name: monofluorophosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orthodontic oral appliance (orthodontic OA)
Study: 7261830
Drug: Bethanechol 25
Normalized name: bethanechol 25 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bethanechol 25 mg 4 times a day
Study: 27835765
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine 300U/mL (Gla-300)
Study: 18335329
Drug: Clomiphene citrate
Normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clomiphene citrate (CC) 50 mg on days 3-5
Study: 11070759
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate 20 mg-SR
Study: 20949341
Drug: Morphine sulfate
Normalized name: Morphine Sulfate
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Morphine sulfate and naltrexone hydrochloride extended release capsules taken intact with water under fed conditions
Study: 11435270
Drug: Long-term antipsychotic
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term antipsychotic treatment
Study: 17619791
Drug: Short-acting beta2
Normalized name: Short-acting sulfonamides
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short-acting beta2 agonists as needed
Study: 15557857
Drug: Timolol maleate
Normalized name: Timolol Maleate
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Timolol maleate gel-forming solution
Study: 11573708
Drug: Antiarrhythmic drugs
Normalized name: ANTIARRHYTHMICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiarrhythmic drugs
Study: 21271182
Drug: Isotonic solution
Normalized name: Isotonic solutions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotonic solution (Gatorade(®))
Study: 11820367
Drug: Nasal immunization
Normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal immunization with glucosyltransferase-enriched preparation (E-GTF)
Study: 30248217
Drug: N9-GP 40
Normalized name: GPS
DrugBank: Galinpepimut-S (DB17271)
Approvals — FDA: no, EMA: no, PMDA: no
Description: N9-GP 40 IU/kg once-weekly prophylaxis
Study: 15374707
Drug: raloxifene hCL
Normalized name: raloxifene HCl
DrugBank: Raloxifene (DB00481)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: raloxifene hCL (60 mg)
Study: 21795635
Drug: Combined bolus
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined bolus infusion of GH or saline and continuous stimulation by saline GH‐releasing hormone (GHRH), GHRP‐2, or both peptides after randomly ordered supplementation with placebo vs. E(2) (estrogen; women) and T (testosterone; men)
Study: 23703041
Drug: Classical music
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Classical music therapy (15-minute sessions, twice a day for three consecutive days)
Study: 30971301
Drug: Definitive concurrent
Normalized name: ESIKA PRO HD COLOR HIGH DEFINITION COLOR SPF 20 KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Definitive concurrent chemoradiotherapy (DCRT)
Study: 28536825
Drug: Intramuscular clodronate
Normalized name: Clodronic acid
DrugBank: Clodronic acid (DB00720)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular clodronate (CLO) 200 mg/day i.m. for 10 days, followed by 200 mg/day i.m. for 6 days after 3 and 6 months, added to usual NSAIDs or analgesic drugs.
Study: 28536825
Drug: Usual treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual treatment with anti-inflammatory or analgesic drugs (Control Group B).
Study: 22327088
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E supplementation (268 mg·d⁻¹)
Study: 10231510
Drug: 100 microg
Normalized name: Digoxin 100 microgram oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 microg recombinant human platelet‐derived growth factor‐BB daily
Study: 25619170
Drug: Low-dose hydrocortisone
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose hydrocortisone therapy
Study: 27869986
Drug: AD +
Normalized name: Stahist AD
DrugBank: Chlorcyclizine (DB08936)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: AD + PE (sertraline plus physical exercise)
Study: 16365065
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (5 mL daily for 3 months)
Study: 9840607
Drug: Oxfendazole (OFZ)
Normalized name: Oxfendazole
DrugBank: Oxfendazole (DB11446)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxfendazole (OFZ) 30 mg/kg
Study: 15203576
Drug: Insulin lispro
Normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin lispro (IL) administered before meals
Study: 2125938
Drug: Acipimox (AC)
Normalized name: acipimox
DrugBank: Acipimox (DB09055)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acipimox (AC) 500 mg with placebo
Study: 17159193
Drug: Delayed zoledronic
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Delayed zoledronic acid (administered when LS or TH T score decreased to less than -2.0 or when a nontraumatic fracture occurred)
Study: 17962050
Drug: Calcium dobesilate
Normalized name: CALCIUM DOBESILATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium dobesilate (500mg capsules twice a day for 3 months)
Study: 19636533
Drug: Intensive insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive insulin therapy (target BG 4.4-6.1 mmol/L)
Study: 12660335
Drug: Sustained-release diltiazem
Normalized name: diltiazem
DrugBank: Diltiazem (DB00343)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sustained-release diltiazem 120 mg twice daily
Study: 12747344
Drug: Oral morphine
Normalized name: morphine Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral morphine (30 mg) plus lorazepam (1 mg)
Study: 12859700
Drug: bupropion SR
Normalized name: Bupropion Hydrochloride 100 MG Oral Tablet, Extended Release, 12 HR [BUPROPION SR]
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: bupropion SR 300 mg daily for 7 weeks
Study: 2049964
Drug: Ofloxacin 300
Normalized name: ofloxacin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ofloxacin 300 mg b.i.d.
Study: 2049964
Drug: Trimethoprim +
Normalized name: Trimethoprim
DrugBank: Trimethoprim (DB00440)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Trimethoprim + Sulfamethoxazole (TMP 800 mg + SMX 160 mg), 1 tablet, b.i.d.
Study: 24496960
Drug: Traditional dosing
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional dosing (for older patients with PNA ≥10 days)
Study: 12105816
Drug: Zinc sulfate
Normalized name: Zinc Sulfate
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Zinc sulfate supplementation (7.7 micromol zinc sulfate, 50 mg elemental zinc) for 90 days
Study: 21163569
Drug: Intravesical BCG
Normalized name: BCG, live, Tice strain
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravesical BCG (81 mg)
Study: 19139780
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose folic acid (5 mg/day)
Study: 19139780
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose folic acid (0.5 mg/day)
Study: 12504938
Drug: Isosorbide mononitrate
Normalized name: Isosorbide Mononitrate
DrugBank: Isosorbide mononitrate (DB01020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide mononitrate 40 mg
Study: 7647732
Drug: Nedocromil sodium
Normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nedocromil sodium 8 mg/24 h
Study: 8388286
Drug: Cimetidine suspension
Normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cimetidine suspension
Study: 11798458
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of consensus interferon (IFN-con1)
Study: 21720656
Drug: Cetaphil RestoradermTM
Normalized name: CETAPHIL
DrugBank: Octocrylene (DB09535)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cetaphil RestoradermTM Moisturizer (CRM) with topical steroid
Study: 28368936
Drug: Computer-controlled continuous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computer-controlled continuous infusion of phenylephrine
Study: 21896097
Drug: Rifaximin 550
Normalized name: rifAXIMin 550 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifaximin 550 mg once daily for 14 days
Study: 7821746
Drug: C-peptide administration
Normalized name: peptide-T
DrugBank: Peptide-T (DB19279)
Approvals — FDA: no, EMA: no, PMDA: no
Description: C-peptide administration
Study: 3062253
Drug: Rapid rotation
Normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapid rotation (change of drugs every 2-3 weeks)
Study: 27267880
Drug: Low-dose rotigotine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose rotigotine (≤6 mg/24 h for early PD or ≤8 mg/24 h for advanced PD)
Study: 27267880
Drug: Low-dose rotigotine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose rotigotine
Study: 26605991
Drug: linagliptin 5
Normalized name: linagliptin 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: linagliptin 5 mg once daily
Study: 12501875
Drug: Ketotifen fumarate
Normalized name: Ketotifen Fumarate
DrugBank: Ketotifen (DB00920)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketotifen fumarate 0.025% ophthalmic solution
Study: 1963650
Drug: Conjugated estrogens
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated estrogens (0.6 mg/kg/day for 5 days)
Study: 9727567
Drug: Saquinavir (SQV)
DrugBank: Saquinavir (DB01232)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saquinavir (SQV) treatment
Study: 19801052
Drug: Twice-daily physiotherapy
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily physiotherapy
Study: 16541783
Drug: 0.2 mg
Normalized name: niacin 0.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg x kg(‐1) LCT propofol
Study: 30149145
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no further treatment)
Study: 16825288
Drug: Low-dose amiodarone
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose amiodarone alone
Study: 348308
Drug: Cis-dichlorodiammineplatinum(II) single
Normalized name: CIS-DIAMMINEDICHLOROPLATINUM II
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cis-dichlorodiammineplatinum(II) single dose of 100 mg/m2 iv every 3-4 weeks
Study: 17522560
Drug: Oral aripiprazole
Normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral aripiprazole
Study: 9564119
Drug: Chlorpromazine (CLO)
Normalized name: Chlorpromazine
DrugBank: Chlorpromazine (DB00477)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chlorpromazine (CLO) (50 mg/day) + Dexamethasone (DEX) (2 mg/day)
Study: 31943693
Drug: Drug-eluting stent
Normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-eluting stent (DES; Medtronic, Minneapolis, Minnesota)
Study: 24857827
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg fluoxetine daily for 3 weeks
Study: 6463391
Drug: Propranolol 40
Normalized name: propranolol 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol 40 mg b.i.d.
Study: 28731567
Drug: 8-week sham
Normalized name: lacosamide
DrugBank: Lacosamide (DB06218)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 8-week sham acupuncture treatment
Study: 7193307
Drug: Levodopa administered
Normalized name: Levodopa
DrugBank: Levodopa (DB01235)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Levodopa administered by mouth
Study: 10355005
Drug: Monthly topical
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly topical fluoride treatments with 2% NaF for two children.
Study: 1769603
Drug: Sublingual nifedipine
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sublingual nifedipine (used only if diastolic pressure of 110 mmHg or more)
Study: 23811112
Drug: Danoprevir 300
Normalized name: Danoprevir
DrugBank: Danoprevir (DB11779)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danoprevir 300 mg every 8 hours
Study: 23811112
Drug: Danoprevir 600
Normalized name: Danoprevir
DrugBank: Danoprevir (DB11779)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danoprevir 600 mg every 12 hours
Study: 23811112
Drug: Danoprevir 900
Normalized name: Danoprevir
DrugBank: Danoprevir (DB11779)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danoprevir 900 mg every 12 hours
Study: 31852712
Drug: Ascorbic acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ascorbic acid (1500 mg), thiamine (100 mg), hydrocortisone (50 mg) every 6 hours for 4 days
Study: 8883124
Drug: Parathyroidectomy followed
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Parathyroidectomy followed by calcitriol therapy (0.25 micrograms b.i.d. for 12 months)
Study: 17161052
Drug: Invasive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Invasive treatment strategy
Study: 15956631
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment strategy
Study: 21641274
Drug: Laboratory-guided preemptive
Normalized name: guaifenesin
DrugBank: Guaifenesin (DB00874)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Laboratory-guided preemptive therapy
Study: 7575754
Drug: Rapid-release film-coated
Normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapid-release film-coated tablet (B)
Study: 8304056
Drug: Indomethacin bolus
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Indomethacin bolus injection followed by continuous infusion
Study: 31542988
Drug: Change over
Normalized name: colloidal oatmeal
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Change over time in TRQ between older and younger participants by treatment arm (CAE and EDU)
Study: 11139541
Drug: Activated charcoal
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activated charcoal (5 g, four times a day, starting 3 hours after pill intake on cycle days 12, 13, and 14)
Study: 6677074
Drug: Multi-therapy
Normalized name: Parasedge Multi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-therapy
Study: 25517348
Drug: Intraarterial treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraarterial treatment plus usual care
Study: 8398292
Drug: BCG-RIVM -
Normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCG-RIVM - 6 weekly instillations
Study: 2974775
Drug: Non-insulin treated
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Non-insulin treated patients
Study: 7745465
Drug: Avoidance of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avoidance of aspirin and NSAIDs
Study: 30043415
Drug: Music therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music therapy during hospitalisation (twice a week for four to six weeks)
Study: 20456191
Drug: Menthol 10%
Normalized name: MENTHOL 10% CREAM,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Menthol 10% solution
Study: 25504995
Drug: AICS-Bud 1
Normalized name: Clove buds
DrugBank: Clove (DB10672)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AICS-Bud 1 mg
Study: 27103548
Drug: Yoga intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Yoga intervention (2× weekly yoga classes for 12 weeks, complemented by regular home practice guided by a manual)
Study: 8602179
Drug: Beta carotene
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta carotene (50 mg on alternate days)
Study: 31732867
Drug: Pre-operative meloxicam
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pre-operative meloxicam administration
Study: 22134736
Drug: Subcutaneous closed-suction
Normalized name: cetylpyridinium
DrugBank: Cetylpyridinium (DB11073)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subcutaneous closed-suction drainage
Study: 11292293
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mycophenolate mofetil (MMF) combined with cyclosporin (CyA) and steroids (Pred)
Study: 15243302
Drug: Subcutaneous treprostinil
Normalized name: Treprostinil
DrugBank: Treprostinil (DB00374)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Subcutaneous treprostinil sodium (10 ng/kg/min for 72 hours)
Study: 15243302
Drug: Subcutaneous treprostinil
Normalized name: Treprostinil
DrugBank: Treprostinil (DB00374)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Subcutaneous treprostinil sodium
Study: 11341175
Drug: Maternal serum
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maternal serum natural antibodies (N‐Ab) of IgG class to proteins MBP, S100, ACBP14/18 and MP65
Study: 1426372
Drug: Gonadotropin-releasing hormone
Normalized name: Gonadotropin-releasing hormone
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gonadotropin-releasing hormone agonists (GnRH-a)
Study: 31520543
Drug: Probiotic lozenges
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic lozenges
Study: 23651846
Drug: Nutrient infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nutrient infusion into duodenum
Study: 12918546
Drug: Valsartan with
Normalized name: Valsartan
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Valsartan with ACE inhibitor and beta-blocker
Study: 2826549
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Lisinopril and HCTZ
Study: 26659583
Drug: HU +
Normalized name: Hu-PHEC Liver
DrugBank: Hu-PHEC Liver (DB18347)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HU + imatinib (HU 500 mg BID + imatinib 400 mg QD)